Its important to ask for help because, on top of affecting your mental health, insomnia can disrupt your blood sugar levels, undermining the effectiveness of Ozempic
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a leading treatment in the fields of diabetes and obesity, with recent preclinical and clinical studies indicating significant benefits in the management and treatment of MASLD
Limitations 1 : 1 : Results should be interpreted with caution because of the retrospective pre-post design without a control or comparator arm and the relatively short follow-up (6 months) Hypoglycemia may have been underreported, as only the clinically significant events were likely to have been captured (eg, no SMBG or CGM data) EMR database analysis as a potential for selection bias that cannot be controlled, as well as EMR data-capture challenges (eg, coding errors, no dosing data) Patients were mainly from the Northwest and Southern US states and therefore may not be representative of the US national landscape Sanofi-sponsored study *Follow-up period 6 months included GLP-1 RA + Toujeo (N=271)
Cagrilintide is a long-acting amylin analog that works through a different satiety circuit, with monotherapy data showing close to 10.8 percent loss over roughly six months
.png)
